Compare Crispr Therapeutics AG (CRSP) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rent the Runway Inc — how do they compare? Crispr Therapeutics AG trades at $50.55 (market cap $4.97B), while Rent the Runway Inc trades at $3.3 (market cap $109.66M). The key difference: Crispr Therapeutics AG is far larger — about 45.3× Rent the Runway Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | RENT | |
|---|---|---|
Market Cap | $4.97B | $109.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $9.39 |
52-Week Low | $44.34 | $3.10 |
Enterprise Value | $3.32B | $269.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
RENT trades at $3.34, down 0.3% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear attractive with a P/E of 0.44 and P/S of 0.18, though negative equity of -$182.5 million raises concerns. Leadership transition is underway with the CEO stepping down in May 2026.
The outlook remains challenging despite revenue growth, as profitability and cash flow are negative. Analyst consensus is mixed with 42% buy ratings but significant debt and negative equity pose substantial risks. The stock offers potential upside if new initiatives improve margins, but execution risk is high amid leadership changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
